Shapiro Gilla K, Guichon Juliet, Kelaher Margaret
Department of Psychology, McGill University, Montreal, Quebec, Canada; Centre for Health Policy, School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia.
Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
Vaccine. 2017 Oct 9;35(42):5700-5707. doi: 10.1016/j.vaccine.2017.07.079.
The National Advisory Committee on Immunization in Canada recommends human papillomavirus (HPV) vaccination for females and males (ages 9-26). In Canada, the HPV vaccine is predominantly administered through publicly funded school-based programs in provinces and territories. This research provides an overview of Canadian provincial and territorial school-based HPV vaccination program administration and vaccination rates, and identifies foreseeable policy considerations.
We searched the academic and grey literature and contacted administrators of provincial and territorial vaccination programs to compile information regarding HPV vaccine program administration and vaccination rates in Canada's 13 provincial and territorial jurisdictions.
As of October 2016, all 13 Canadian jurisdictions vaccinate girls, and six jurisdictions include boys in school-based publicly funded HPV vaccination programs. Eleven jurisdictions administer the HPV vaccine in a two-dose schedule. The quadrivalent vaccine (HPV4) has been the vaccine predominantly used in Canada; however, the majority of provinces will likely adopt the nonavalent vaccine in the future. According to available data, vaccination uptake among females ranged between 46.7% and 93.9%, while vaccination uptake among males (in programs with available data to date) ranged between 75.0% and 87.4%.
Future research and innovation will beneficially inform Canadian jurisdictions when considering whether to administer the nonavalent vaccine, whether to implement a two or one-dose vaccination schedule, and how to improve uptake and rates of completion. The usefulness of standardizing methodologies for collecting and reporting HPV vaccination coverage and implementing a national registry were identified as important priorities.
加拿大国家免疫咨询委员会建议对女性和男性（9至26岁）接种人乳头瘤病毒（HPV）疫苗。在加拿大，HPV疫苗主要通过各省和地区的公立学校项目进行接种。本研究概述了加拿大各省和地区基于学校的HPV疫苗接种项目管理及接种率，并确定了可预见的政策考量因素。
我们检索了学术文献和灰色文献，并联系了各省和地区疫苗接种项目的管理人员，以收集有关加拿大13个省和地区辖区HPV疫苗项目管理及接种率的信息。
截至2016年10月，加拿大所有13个辖区都为女孩接种疫苗，6个辖区将男孩纳入基于学校的公立HPV疫苗接种项目。11个辖区按照两剂次的程序接种HPV疫苗。四价疫苗（HPV4）一直是加拿大主要使用的疫苗；然而，大多数省份未来可能会采用九价疫苗。根据现有数据，女性的接种率在46.7%至93.9%之间，而男性的接种率（在有数据的项目中）在75.0%至87.4%之间。
未来的研究和创新将有助于为加拿大各辖区在考虑是否接种九价疫苗、是否实施两剂次或一剂次接种程序以及如何提高接种率和完成率时提供有益参考。确定了标准化收集和报告HPV疫苗接种覆盖率的方法以及建立国家登记系统的重要性。
